
    
      The purpose of this study is to evaluate the combined effect of parenteral treprostinil (TRE)
      and riociguat (RIO) versus parenteral TRE alone on right ventricular (RV)-pulmonary artery
      (PA) interaction (RVPA coupling) and global RV function in patients with advanced pulmonary
      arterial hypertension (PAH).
    
  